Cardiomyogenic Differentiation of Human Dental Follicle-derived Stem Cells by Suberoylanilide Hydroxamic Acid and Their In Vivo Homing Property
Open Access
- 1 January 2016
- journal article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 13 (11) , 841-852
Abstract
The purpose of the present study was to investigate the in vitro cardiomyogenic differentiation potential of human dental follicle-derived stem cells (DFCs) under the influence of suberoylanilide hydroxamic acid (SAHA), a member of the histone deacetylase inhibitor family, and analyze the in vivo homing capacity of induced cardiomyocytes (iCMs) when transplanted systemically. DFCs from extracted wisdom teeth showed mesenchymal stem cell (MSC) characteristics such as plate adherent growing, expression of MSC markers (CD44, CD90, and CD105), and mesenchymal lineage-specific differentiation potential. Adding SAHA to the culture medium induced the successful in vitro differentiation of DFCs into cardiomyocytes. These iCMs expressed cardiomyogenic markers, including alpha-smooth muscle actin (α-SMA), cardiac muscle troponin T (TNNT2), Desmin, and cardiac muscle alpha actin (ACTC1), at both the mRNA and protein level. For the assessment of homing capacity, PKH26 labeled iCMs were intraperitoneally injected (1×106 cells in 100 µL of PBS) into the experimental mice, and the ratios of PKH26 positive cells to the total number of injected cells, in multiple organs were determined. The calculated homing ratios, 14 days after systemic cell transplantation, were 5.6 ± 1.0%, 3.6 ± 1.1%, and 11.6 ± 2.7% in heart, liver, and kidney respectively. There was no difference in the serum levels of interleukin-2 and interleukin-10 at 14 days after transplantation, between the experimental (iCM injected) and control (no injection or PBS injection) groups. These results demonstrate that DFCs can be an excellent source for cardiomyocyte differentiation and regeneration. Moreover, the iCMs can be delivered into heart muscle via systemic administration without eliciting inflammatory or immune response. This can serve as the pilot study for further investigations into the in vitro cardiomyogenic differentiation potential of DFCs under the influence of SAHA and the in vivo homing capacity of the iCMs into the heart muscle, when injected systemically.Keywords
This publication has 33 references indexed in Scilit:
- Mesenchymal Stem Cells for Cardiac Regenerative Therapy: Optimization of Cell Differentiation StrategyStem Cells International, 2015
- Mesenchymal Stem Cells Migration Homing and TrackingStem Cells International, 2013
- Mesenchymal Stem Cell treatment for autoimmune diseases: a critical reviewBiological Research, 2012
- In Vitro and In Vivo Osteogenesis of Porcine Skin-Derived Mesenchymal Stem Cell–like Cells with a Demineralized Bone and Fibrin Glue ScaffoldTissue Engineering Part A, 2010
- Protective Effect of Human Amniotic Fluid Stem Cells in an Immunodeficient Mouse Model of Acute Tubular NecrosisPLOS ONE, 2010
- Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cellsExperimental Cell Research, 2009
- Cardiomyogenic Potential of Human Adult Bone Marrow Mesenchymal Stem Cells in VitroThe Thoracic and Cardiovascular Surgeon, 2008
- Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injuryKidney International, 2007
- Role of histone deacetylase inhibitors in the treatment of cancer (Review).International Journal of Oncology, 2004
- Histone Deacetylase Inhibitors and Anticancer TherapyCurrent Medicinal Chemistry - Anti-Cancer Agents, 2002